{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:15:08Z","timestamp":1789398908007,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["5U54GM104942-05"],"award-info":[{"award-number":["5U54GM104942-05"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ibrutinib is a Bruton\u2019s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flutter). It is known that patients with cardiovascular disease (CVD) are at an increased risk for developing atrial arrhythmia. However, the rate of atrial arrhythmia in patients with pre-existing CVD treated with ibrutinib is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study examined whether patients with pre-existing CVD are at a higher risk for developing atrial arrhythmias compared to those without prior CVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-institution retrospective chart review of patients with no prior history of atrial arrhythmia treated with ibrutinib from 2012 to 2020 was performed. Patients were grouped into two cohorts: those with CVD (known history of coronary artery disease, heart failure, pulmonary hypertension, at least moderate valvular heart disease, or device implantation) and those without CVD. The primary outcome was incidence of atrial arrhythmia, and the secondary outcomes were all-cause mortality, risk of bleeding, and discontinuation of ibrutinib. The predictors of atrial arrhythmia (namely atrial fibrillation) were assessed using logistic regression. A Cox-Proportional Hazard model was created for mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients were followed for a median of 1.1\u2009years. Among 217 patients treated with ibrutinib, the rate of new-onset atrial arrhythmia was nearly threefold higher in the cohort with CVD compared to the cohort without CVD (17% vs 7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Patients with CVD also demonstrated increased adjusted all-cause mortality (OR 1.9, 95% CI 1.06-3.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) and decreased survival probability (43% vs 54%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) compared to those without CVD over the follow-up period. There were no differences in risk of bleeding or discontinuation between the two cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-existing cardiovascular disease was associated with significantly higher rates of atrial arrhythmia and mortality in patients with hematological malignancies managed with ibrutinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-021-00125-8","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T03:02:53Z","timestamp":1637290973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib"],"prefix":"10.1186","volume":"7","author":[{"given":"Juan Carlo","family":"Avalon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Fuqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Deskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelby","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Inderbitzin-Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Veltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Kanate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midhun","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"125_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NELMoa1306220","volume":"369","author":"M Wang","year":"2013","unstructured":"Wang M, Rule S, et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316. https:\/\/doi.org\/10.1056\/NELMoa1306220.","journal-title":"N Engl J Med"},{"key":"125_CR2","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus Chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1812836.","journal-title":"N Engl J Med"},{"key":"125_CR3","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","volume":"378","author":"M Dimopoulos","year":"2018","unstructured":"Dimopoulos M, Tedeschi A, et al. Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom\u2019s Macroglobulinemia. N Engl J Med. 2018;378:2399\u2013410. https:\/\/doi.org\/10.1056\/NEJMoa1802917.","journal-title":"N Engl J Med"},{"key":"125_CR4","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243\u201350. https:\/\/doi.org\/10.1182\/blood-2017-07-793786.","journal-title":"Blood."},{"key":"125_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40265-015-0380-3","volume":"75","author":"ES Kim","year":"2015","unstructured":"Kim ES, Dhillon S. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic Leukaemia. Drugs. 2015;75:769\u201376 https:\/\/doi.org\/10.1007\/s40265-015-0380-3.","journal-title":"Drugs."},{"issue":"5","key":"125_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835\u201347. https:\/\/doi.org\/10.1111\/jth.13651.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"125_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/cid\/ciy175","volume":"67","author":"T Varughese","year":"2018","unstructured":"Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving Ibrutinib for treatment of lymphoid Cancer. Clin Infect Dis. 2018;67(5):687\u201392. https:\/\/doi.org\/10.1093\/cid\/ciy175.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"125_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/leu.2015.273","volume":"30","author":"KA Rogers","year":"2016","unstructured":"Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30(2):346\u201350. https:\/\/doi.org\/10.1038\/leu.2015.273.","journal-title":"Leukemia."},{"key":"125_CR9","doi-asserted-by":"publisher","unstructured":"Gashonia LM, Carver JR, O\u2019Quinn R, et al. Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience. J Clin Oncol. 2017;35(15_suppl):7525. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.7525","DOI":"10.1200\/JCO.2017.35.15_suppl.7525"},{"issue":"22","key":"125_CR10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919\u201328. https:\/\/doi.org\/10.1182\/blood.2019000840.","journal-title":"Blood."},{"issue":"7","key":"125_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1177\/1078155217718617","volume":"24","author":"KS Titus-Rains","year":"2018","unstructured":"Titus-Rains KS, Brown JN, Hammond JM. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia\/small lymphocytic lymphoma and mantle cell lymphoma: a case series and review of the literature. J Oncol Pharm Pract. 2018;24(7):544\u20139.","journal-title":"J Oncol Pharm Pract"},{"issue":"18","key":"125_CR12","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","volume":"129","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Yu L, Glynn RJ, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581\u20134. https:\/\/doi.org\/10.1182\/blood-2016-10-742437.","journal-title":"Blood."},{"issue":"12","key":"125_CR13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"4","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491\u2013500. https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004.","journal-title":"JACC Clin Electrophysiol"},{"issue":"11","key":"125_CR14","first-page":"970","volume":"30","author":"A Vrontikis","year":"2016","unstructured":"Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed algorithm for managing Ibrutinib-related atrial fibrillation. Oncology (Williston Park). 2016;30(11):970\u2013C3.","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"125_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cjca.2017.12.001","volume":"34","author":"JM Tuomi","year":"2018","unstructured":"Tuomi JM, Xenocostas A, Jones DL. Increased susceptibility for atrial and ventricular cardiac arrhythmias in mice treated with a single high dose of Ibrutinib. Can J Cardiol. 2018;34(3):337\u201341. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.001.","journal-title":"Can J Cardiol"},{"key":"125_CR16","doi-asserted-by":"publisher","unstructured":"McMullen JR, Boey EJH, Ooi JYY, Seymour JF, Keating MJ, Tam CS; Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014;124(25):3829\u20133830.\u00a0https:\/\/doi.org\/10.1182\/blood-2014-10-604272","DOI":"10.1182\/blood-2014-10-604272"},{"issue":"3","key":"125_CR17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","volume":"175","author":"L Pretorius","year":"2009","unstructured":"Pretorius L, Du XJ, Woodcock EA, et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 2009;175(3):998\u20131009. https:\/\/doi.org\/10.2353\/ajpath.2009.090126.","journal-title":"Am J Pathol"},{"issue":"3","key":"125_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/NRL.0b013e31815cffae","volume":"14","author":"K Lakshminarayan","year":"2008","unstructured":"Lakshminarayan K, Anderson DC, Herzog CA, Qureshi AI. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist. 2008;14(3):143\u201350. https:\/\/doi.org\/10.1097\/NRL.0b013e31815cffae.","journal-title":"Neurologist."},{"key":"125_CR19","doi-asserted-by":"publisher","unstructured":"Michniewicz E, Mlodawska E, Lopatowska P, et al., Patients with atrial fibrillation and coronary artery disease \u2013 Double trouble. Adv Med Sci. 2018;63 (1):30-35.\u00a0https:\/\/doi.org\/10.1016\/j.advms.2017.06.005.","DOI":"10.1016\/j.advms.2017.06.005"},{"issue":"10","key":"125_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrcardio.2016.118","volume":"13","author":"S Nattel","year":"2016","unstructured":"Nattel S, Dobrev D. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. Nat Rev Cardiol. 2016;13(10):575\u201390. https:\/\/doi.org\/10.1038\/nrcardio.2016.118.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"125_CR21","doi-asserted-by":"publisher","first-page":"16016","DOI":"10.1038\/nrdp.2016.16","volume":"2","author":"GYH Lip","year":"2016","unstructured":"Lip GYH, Fauchier L, Freedman SB, et al. Atrial fibrillation. Nat Rev Dis Prim. 2016;2(1):16016. https:\/\/doi.org\/10.1038\/nrdp.2016.16.","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"125_CR22","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"J Brown","year":"2017","unstructured":"Brown J, Moslehi J, O\u2019Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796\u2013805. https:\/\/doi.org\/10.3324\/haematol.2017.171041.","journal-title":"Haematologica."},{"issue":"1","key":"125_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","volume":"128","author":"D Leong","year":"2016","unstructured":"Leong D, Caron F. Christopher Hillis, Annie Duan, Jeff S. Healey, Graeme Fraser, Deborah Siegal; the risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138\u201340. https:\/\/doi.org\/10.1182\/blood-2016-05-712828.","journal-title":"Blood."},{"key":"125_CR24","doi-asserted-by":"publisher","unstructured":"Diamond A, Bensken WP, Dong W, Markt SC, Koroukian SM, Caimi P. Three-Fold Risk of Atrial Fibrillation in Ibrutinib Treated CLL Patients without Increased Risk of Stroke: A SEER-Medicare Database Analysis. Blood. 2020;136(Supplement 1):18\u201319. https:\/\/doi.org\/10.1182\/blood-2020-141287","DOI":"10.1182\/blood-2020-141287"},{"key":"125_CR25","doi-asserted-by":"publisher","unstructured":"Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739\u20131748.\u00a0https:\/\/doi.org\/10.1182\/bloodadvances.2017009720.","DOI":"10.1182\/bloodadvances.2017009720"},{"key":"125_CR26","doi-asserted-by":"publisher","unstructured":"Reda G, Fattizzo B, Cassin R, et al. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: A prospective study.\u00a0J Hematol Oncol Published online 2018.\u00a0https:\/\/doi.org\/10.1186\/s13045-018-0626-0.","DOI":"10.1186\/s13045-018-0626-0"},{"issue":"8","key":"125_CR27","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1172\/JCI46315","volume":"121","author":"R Wakili","year":"2011","unstructured":"Wakili R, Voigt N, K\u00e4\u00e4b S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest. 2011;121(8):2955\u201368. https:\/\/doi.org\/10.1172\/JCI46315.","journal-title":"J Clin Invest"},{"issue":"8","key":"125_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jacc.2007.09.064","volume":"51","author":"B Burstein","year":"2008","unstructured":"Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.064.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"125_CR29","first-page":"483","volume":"39","author":"S Parmar","year":"2014","unstructured":"Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014;39(7):483\u2013519.","journal-title":"P T"},{"issue":"25","key":"125_CR30","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1509388.","journal-title":"N Engl J Med"},{"issue":"9","key":"125_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.hrthm.2010.05.032","volume":"7","author":"T Yang","year":"2010","unstructured":"Yang T, Yang P, Roden DM, Darbar D. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm. 2010;7(9):1246\u201352. https:\/\/doi.org\/10.1016\/j.hrthm.2010.05.032.","journal-title":"Heart Rhythm"},{"issue":"9","key":"125_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","volume":"16","author":"L Jiang","year":"2019","unstructured":"Jiang L, Li L, Ruan Y, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm. 2019;16(9):1374\u201382. https:\/\/doi.org\/10.1016\/j.hrthm.2019.04.008.","journal-title":"Heart Rhythm"},{"key":"125_CR33","doi-asserted-by":"crossref","unstructured":"Ganatra S, Sharma A, Shah S, et al. Ibrutinib-Associated Atrial Fibrillation. J Am Coll Cardiol Clin Electrophysiol. 2018;4(12):1491\u20131500. 10.1016\/j.jacep.2018.06.004.","DOI":"10.1016\/j.jacep.2018.06.004"},{"issue":"2","key":"125_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","volume":"165","author":"YF Hu","year":"2013","unstructured":"Hu YF, Liu CJ, Chang PM, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013;165(2):355\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2012.08.036.","journal-title":"Int J Cardiol"},{"issue":"6","key":"125_CR35","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1080\/10428194.2016.1251592","volume":"58","author":"HD Finnes","year":"2017","unstructured":"Finnes HD, Chaffee KG, Call TG, et al. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 2017;58(6):1376\u201383. https:\/\/doi.org\/10.1080\/10428194.2016.1251592.","journal-title":"Leuk Lymphoma"},{"key":"125_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15384047.2017.1394554","volume":"19","author":"AR Mato","year":"2018","unstructured":"Mato AR, Clasen S, Pickens P, et al. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biol Ther. 2018;19:1\u20132.","journal-title":"Cancer Biol Ther"},{"key":"125_CR37","doi-asserted-by":"publisher","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PLoS One. 2019;14(2).\u00a0\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0211228","DOI":"10.1371\/journal.pone.0211228"},{"key":"125_CR38","doi-asserted-by":"crossref","unstructured":"Jones J, George B, Peterson CB, et al. Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL). J Clin Oncol. 2019;37(15).","DOI":"10.1200\/JCO.2019.37.15_suppl.e19009"},{"key":"125_CR39","doi-asserted-by":"publisher","unstructured":"Roeker LE, Sarraf Yazdy M, Rhodes J, et al. Hypertension in patients treated with Ibrutinib for chronic lymphocytic leukemia. JAMA Netw Open. 2019;2(12):e1916326\u20136. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16326.","DOI":"10.1001\/jamanetworkopen.2019.16326"},{"key":"125_CR40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/hon.2503","volume":"36","author":"G Boriani","year":"2018","unstructured":"Boriani G, Corradini P, Cuneo A, et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol. 2018;36:624\u201332.","journal-title":"Hematol Oncol"},{"issue":"12","key":"125_CR41","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","volume":"100","author":"AH Lipsky","year":"2015","unstructured":"Lipsky AH, Farooqui MZH, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571\u20138. https:\/\/doi.org\/10.3324\/haematol.2015.126672.","journal-title":"Haematologica."},{"issue":"12","key":"125_CR42","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/cncr.30596","volume":"123","author":"P Jain","year":"2017","unstructured":"Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268\u201373. https:\/\/doi.org\/10.1002\/cncr.30596.","journal-title":"Cancer."},{"key":"125_CR43","doi-asserted-by":"publisher","unstructured":"Khalid S, Yasar S, Khalid A, Spiro TP, Haddad A, Daw H. Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience. Cureus. 2018;10(5). https:\/\/doi.org\/10.7759\/cureus.2701.","DOI":"10.7759\/cureus.2701"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-021-00125-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-021-00125-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-021-00125-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T03:04:28Z","timestamp":1637291068000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-021-00125-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["125"],"URL":"https:\/\/doi.org\/10.1186\/s40959-021-00125-8","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent was obtained from our health systems\u2019 Institutional Review Boards (IRB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}